Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors

DiscussionAβ misfolding in blood plasma was a strong, specific risk prediction marker for clinical AD even many years before diagnosis in a community-based setting.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research

Related Links:

Authors: Nikolac Perkovic M, Pivac N Abstract Alzheimer's disease is a complex and heterogeneous, severe neurodegenerative disorder and the predominant form of dementia, characterized by cognitive disturbances, behavioral and psychotic symptoms, progressive cognitive decline, disorientation, behavioral changes, and death. Genetic background of Alzheimer's disease differs between early-onset familial Alzheimer's disease, other cases of early-onset Alzheimer's disease, and late-onset Alzheimer's disease. Rare cases of early-onset familial Alzheimer's diseases are caused by high-penetrant mutations in genes coding for...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
(Technical University of Denmark) Scientists prove that ergothioneine, an important compound that may be used to delay the onset of diseases such as Alzheimer's and dementia, can be produced in baker's yeast.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Authors: Kim YG, Park DG, Moon SY, Jeon JY, Kim HJ, Kim DJ, Lee KW, Han SJ Abstract BACKGROUND: Type 2 diabetes mellitus (T2DM) is associated with an increased risk for dementia. The effects of hypoglycemia on dementia are controversial. Thus, we evaluated whether hypoglycemia increases the risk for dementia in senior patients with T2DM. METHODS: We used the Korean National Health Insurance Service Senior cohort, which includes>10% of the entire senior population of South Korea. In total, 5,966 patients who had ever experienced at least one episode of hypoglycemia were matched with those who had not, using p...
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
We reported dichotomous outcomes as risk ratio (RR) with 95% CI. We assessed the strength of the available evidence using the GRADE approach. MAIN RESULTS: We identified six randomised controlled trials with a total of 597 participants that were eligible for inclusion in the 2013 review. No new studies were eligible for inclusion in this update. Participants in the included studies, where dementia severity was reported, had mild to moderate severity of vascular dementia (four trials). The included studies tested varying doses and duration of Cerebrolysin treatment. Follow-up ranged from 15 days to three years. Five of...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Nicotinamide phosphoribosyltransferase‑related signaling pathway in early Alzheimer's disease mouse models. Mol Med Rep. 2019 Oct 30;: Authors: Xing S, Hu Y, Huang X, Shen D, Chen C Abstract Alzheimer's disease (AD) is a neurodegenerative disease of the central nervous system that is characterized by progressive cognitive dysfunction and which ultimately leads to dementia. Studies have shown that energy dysmetabolism contributes significantly to the pathogenesis of a variety of aging‑associated diseases and degenerative diseases of the nervous system, including AD. One focus of research thus has be...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
When we think of dementia, we think of memory loss, but that's vastly oversimplifying it. Most people have heard of Alzheimer's, but there are other types of dementia too, says DR ELLIE..
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
DiscussionCMDs, especially when comorbid, are associated with increased dementia risk; however, leisure activities and social integration mitigate this risk.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Aldo Ceresa, 66, who lives near Oxford, had over 30 years' experience in dentistry and oral surgery when he began making mistakes at work. He later joined a clinical trial of a new drug, aducanumab.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
(Regenstrief Institute) Regenstrief Institute research scientists Christopher Callahan, M.D., and Alexia Torke, M.D., will play a key role in a major nationwide effort to improve healthcare and quality of life for people with Alzheimer's disease and related dementias. The project, funded by the National Institute on Aging, will create a massive collaborative research incubator to develop trials aimed at evaluating interventions for the disease that affects more than 5 million Americans. Drs. Callahan and Torke will lead the Training Core of the IMPACT Collaboratory.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Despite recent setbacks, disease-modifying treatments (DMTs) for Alzheimer disease (AD) might become available within a few years. These DMTs are likely to be used in the early stages of AD to avoid the progression to manifest dementia, which implies that a large reservoir of prevalent cases would need to be evaluated when DMTs first become available. Primary care providers (PCPs) would play a vital role in managing the patient flow to specialty care. We review the literature on diagnostic tests that could be used by PCPs and estimate the impact of different testing approaches on demand for specialty care. While many tests...
Source: Journal of the American Board of Family Medicine - Category: Primary Care Authors: Tags: Special Communication Source Type: research
More News: Alzheimer's | Dementia | Geriatrics